Climb Bio (CLYM) Expected to Announce Earnings on Wednesday

Key Points

• Climb Bio is set to announce its Q2 2025 earnings on August 13, with expected earnings of ($0.19) per share.
• The company's last reported earnings were ($0.31) per share, missing analysts' expectations by ($0.16).
• Equities analysts have given Climb Bio a "buy" rating and an "outperform" rating with a price target of $10.00.

Climb Bio (NASDAQ:CLYM - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.

Climb Bio (NASDAQ:CLYM - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.16). On average, analysts expect Climb Bio to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Climb Bio Stock Down 4.0%

Shares of NASDAQ CLYM traded down $0.07 during trading on Thursday, reaching $1.68. 271,211 shares of the company traded hands, compared to its average volume of 493,332. The firm has a 50 day simple moving average of $1.36 and a 200-day simple moving average of $1.38. Climb Bio has a 52-week low of $1.05 and a 52-week high of $8.79. The stock has a market capitalization of $113.53 million, a PE ratio of -0.71 and a beta of -0.11.

Institutional Investors Weigh In On Climb Bio

A hedge fund recently bought a new stake in Climb Bio stock. Goldman Sachs Group Inc. acquired a new stake in Climb Bio, Inc. (NASDAQ:CLYM - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 120,742 shares of the company's stock, valued at approximately $147,000. Goldman Sachs Group Inc. owned approximately 0.18% of Climb Bio as of its most recent SEC filing. 69.76% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CLYM has been the topic of several research analyst reports. Oppenheimer began coverage on Climb Bio in a report on Friday, June 6th. They set an "outperform" rating and a $10.00 price target on the stock. BTIG Research initiated coverage on Climb Bio in a research report on Thursday, May 22nd. They set a "buy" rating for the company.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.